efficacy and safety of mirabegron add on treatment to solifenacin in incontinent OAB subjects with an inadequate response to intial 4 week solifenacin monotherapy

---

ESEN A. A., drake m., athanasiou s., herholdt c., saleem t., huang m., ...Daha Fazla

Annual Meeting of the American-Urological-Association (AUA), 15 - 19 Mayıs 2015, (Tam Metin Bildiri)

• Yayın Türü: Bildiri / Tam Metin Bildiri
• Dokuz Eylül Üniversitesi Adresli: Evet